Answers are grounded in this paper and cite their sources.
Enteroccocci have emerged as an important cause of nosocomial infections. Infections caused by multiresistant enterococci are treated with vancomycin or another glycopeptide. In recent years the usage of vancomycin and the isolation rate of vancomycin-resistant enterococci (VRE) have steadily increased in both Europe and the United States (8). Despite the fact that VRE infections are a hospital problem and the human usage of glycopeptides is in hospitals, VRE have been isolated from the fecal flora of healthy humans without a known hospital connection, from animals, and from the environment (1, 5, 9). One of the few options for treatment of vancomycin-resistantEnterococcus faecium infection is quinopristin-dalfopristin, a mixture (30:70 ratio) of two streptogramins: dalfopristin (streptogramin A) and quinopristin (streptogramin B) (6). A related mixed compound virginiamycin has been used in Europe for many years as a feed additive to enhance growth in food animals. High numbers of virginiamycin-resistant E. faecium have been isolated from the feces of food animals, and these were also resistant to quinopristin-dalfopristin, indicating cross-resistance between virginiamycin and quinopristin-dalfopristin (2, 13, 15).
No takes yet. Share an insight, caveat, or question.
Hammerum et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: